The FDA approved the first “radioligand equivalent” generic to Novartis’ Lutathera, setting up direct regulatory and commercial rivalry in theranostics. Curium received approval for a radioligand equivalent intended for the same treatment category as Lutathera. The approval is expected to pressure pricing and pipeline planning across the sector, especially for companies developing next-generation imaging and radiotherapeutic products. With regulatory frameworks for radioligand equivalents now in place, sponsors may increasingly design programs around equivalence pathways and differentiation through targeted improvements in imaging performance, manufacturing, or therapy protocols.